Vanguard Group Inc. Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Vanguard Group Inc. reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,286,346 shares of the biopharmaceutical company’s stock after selling 33,944 shares during the quarter. Vanguard Group Inc. owned about 8.45% of Regeneron Pharmaceuticals worth $6,614,943,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $34,468,000. Umpqua Bank boosted its position in shares of Regeneron Pharmaceuticals by 7.6% during the 4th quarter. Umpqua Bank now owns 1,534 shares of the biopharmaceutical company’s stock valued at $1,060,000 after acquiring an additional 108 shares during the last quarter. Forefront Wealth Management Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at approximately $2,206,000. Mizuho Securities USA LLC boosted its position in shares of Regeneron Pharmaceuticals by 45.0% during the 4th quarter. Mizuho Securities USA LLC now owns 9,977 shares of the biopharmaceutical company’s stock valued at $7,107,000 after acquiring an additional 3,096 shares during the last quarter. Finally, Quantbot Technologies LP boosted its position in shares of Regeneron Pharmaceuticals by 266.7% during the 4th quarter. Quantbot Technologies LP now owns 528 shares of the biopharmaceutical company’s stock valued at $376,000 after acquiring an additional 384 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on REGN. Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Citigroup lowered their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Finally, Wells Fargo & Company lowered their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Price Performance

REGN opened at $658.48 on Monday. The business’s 50-day moving average is $689.43 and its two-hundred day moving average is $813.15. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm has a market capitalization of $71.99 billion, a PE ratio of 17.20, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the company posted $11.86 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.53%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.